Browse ENO1

Summary
SymbolENO1
Nameenolase 1, (alpha)
Aliases PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Cell membrane Cytoplasm, myofibril, sarcomere, M line Note=Can translocate to the plasma membrane in either the homodimeric (alpha/alpha) or heterodimeric (alpha/gamma) form. ENO1 is localized to the M line.; SUBCELLULAR LOCATION: Isoform MBP-1: Nucleus.
Domain PF00113 Enolase
PF03952 Enolase
Function

Multifunctional enzyme that, as well as its role in glycolysis, plays a part in various processes such as growth control, hypoxia tolerance and allergic responses. May also function in the intravascular and pericellular fibrinolytic system due to its ability to serve as a receptor and activator of plasminogen on the cell surface of several cell-types such as leukocytes and neurons. Stimulates immunoglobulin production.; FUNCTION: MBP1 binds to the myc promoter and acts as a transcriptional repressor. May be a tumor suppressor.

> Gene Ontology
 
Biological Process GO:0001558 regulation of cell growth
GO:0005996 monosaccharide metabolic process
GO:0006006 glucose metabolic process
GO:0006007 glucose catabolic process
GO:0006090 pyruvate metabolic process
GO:0006091 generation of precursor metabolites and energy
GO:0006094 gluconeogenesis
GO:0006096 glycolytic process
GO:0006165 nucleoside diphosphate phosphorylation
GO:0006732 coenzyme metabolic process
GO:0006733 oxidoreduction coenzyme metabolic process
GO:0006734 NADH metabolic process
GO:0006735 NADH regeneration
GO:0006757 ATP generation from ADP
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009123 nucleoside monophosphate metabolic process
GO:0009126 purine nucleoside monophosphate metabolic process
GO:0009132 nucleoside diphosphate metabolic process
GO:0009135 purine nucleoside diphosphate metabolic process
GO:0009141 nucleoside triphosphate metabolic process
GO:0009144 purine nucleoside triphosphate metabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009161 ribonucleoside monophosphate metabolic process
GO:0009167 purine ribonucleoside monophosphate metabolic process
GO:0009179 purine ribonucleoside diphosphate metabolic process
GO:0009185 ribonucleoside diphosphate metabolic process
GO:0009199 ribonucleoside triphosphate metabolic process
GO:0009205 purine ribonucleoside triphosphate metabolic process
GO:0009615 response to virus
GO:0016049 cell growth
GO:0016051 carbohydrate biosynthetic process
GO:0016052 carbohydrate catabolic process
GO:0019318 hexose metabolic process
GO:0019319 hexose biosynthetic process
GO:0019320 hexose catabolic process
GO:0019362 pyridine nucleotide metabolic process
GO:0019674 NAD metabolic process
GO:0030308 negative regulation of cell growth
GO:0042278 purine nucleoside metabolic process
GO:0044282 small molecule catabolic process
GO:0044283 small molecule biosynthetic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0044724 single-organism carbohydrate catabolic process
GO:0045926 negative regulation of growth
GO:0046031 ADP metabolic process
GO:0046034 ATP metabolic process
GO:0046128 purine ribonucleoside metabolic process
GO:0046364 monosaccharide biosynthetic process
GO:0046365 monosaccharide catabolic process
GO:0046496 nicotinamide nucleotide metabolic process
GO:0046939 nucleotide phosphorylation
GO:0051186 cofactor metabolic process
GO:0061615 glycolytic process through fructose-6-phosphate
GO:0061620 glycolytic process through glucose-6-phosphate
GO:0061621 canonical glycolysis
GO:0061718 glucose catabolic process to pyruvate
GO:0072524 pyridine-containing compound metabolic process
GO:1901657 glycosyl compound metabolic process
Molecular Function GO:0000287 magnesium ion binding
GO:0004634 phosphopyruvate hydratase activity
GO:0016829 lyase activity
GO:0016835 carbon-oxygen lyase activity
GO:0016836 hydro-lyase activity
GO:0045296 cadherin binding
GO:0050839 cell adhesion molecule binding
GO:0051020 GTPase binding
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0000015 phosphopyruvate hydratase complex
GO:0005913 cell-cell adherens junction
GO:0030016 myofibril
GO:0030017 sarcomere
GO:0031430 M band
GO:0031672 A band
GO:0043292 contractile fiber
GO:0044445 cytosolic part
GO:0044449 contractile fiber part
> KEGG and Reactome Pathway
 
KEGG hsa03018 RNA degradation
hsa04066 HIF-1 signaling pathway
hsa00010 Glycolysis / Gluconeogenesis
hsa01100 Metabolic pathways
hsa01200 Carbon metabolism
hsa01230 Biosynthesis of amino acids
Reactome R-HSA-70263: Gluconeogenesis
R-HSA-70326: Glucose metabolism
R-HSA-70171: Glycolysis
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
Summary
SymbolENO1
Nameenolase 1, (alpha)
Aliases PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ENO1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ENO1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29308319Pancreatic Carcinoma; Lung CarcinomaPromote immunityCitrullinated α-enolase is an effective target for anti-cancer immunity.
23333712pancreatic carcinomaPromote immunityIn a genetic model of pancreatic carcinoma, vaccination with ENO1 DNA elicits humoral and cellular immune responses against tumors, delays tumor progression, and significantly extends survival
Summary
SymbolENO1
Nameenolase 1, (alpha)
Aliases PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ENO1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolENO1
Nameenolase 1, (alpha)
Aliases PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ENO1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6320.072
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.720.873
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.560.859
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2930.531
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.220.939
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3930.919
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0930.879
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.20.942
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.450.881
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2920.932
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1860.972
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1430.173
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ENO1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolENO1
Nameenolase 1, (alpha)
Aliases PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ENO1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolENO1
Nameenolase 1, (alpha)
Aliases PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ENO1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ENO1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolENO1
Nameenolase 1, (alpha)
Aliases PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ENO1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolENO1
Nameenolase 1, (alpha)
Aliases PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ENO1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolENO1
Nameenolase 1, (alpha)
Aliases PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ENO1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolENO1
Nameenolase 1, (alpha)
Aliases PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ENO1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ENO1.
ID Name Drug Type Targets #Targets
DB01593ZincSmall MoleculeA1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......119
DB09130CopperSmall MoleculeA1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......141
DB11638ArtenimolSmall MoleculeACTG1, ALB, ALDH7A1, ALDOA, ANXA2, ATP5A1, ATP5L, ATP5O, CAST, CCT ......79